Business Context and Reporting Period
Anixa Biosciences, Inc. (ANIX) is a biotechnology company developing oncology therapies and vaccines. The company operates through three segments: Cancer Vaccines, CAR-T Therapeutics (via subsidiary Certainty Therapeutics), and Other. This Form 10-Q covers the quarterly period ended April 30, 2025.
Key operational milestones include:
- CAR-T Therapeutics: Dose-escalation Phase 1 trials for ovarian cancer are ongoing. The company treated patients in the third dose cohort (10x higher dose) between November 2024 and February 2025 and is preparing to enroll patients in a fourth cohort (30x higher dose).
- Cancer Vaccines: Phase 1 trials for a breast cancer vaccine (targeting triple-negative breast cancer) are nearing enrollment completion, with final data expected in December 2025. The company is preparing to initiate a Phase 2 trial.
- Revenue Model: The company has generated no revenue from its therapeutic or vaccine programs. Historical revenue was derived from patent licensing and litigation settlements.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended April 30, 2025 |
Six Months Ended April 30, 2025 |
Six Months Ended April 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Total Operating Expenses | $3,003 | $6,389 | $7,076 |
| Net Loss | $(2,813) | $(6,026) | $(6,470) |
| Net Loss Attributable to Common Shareholders | $(2,790) | $(5,974) | $(6,394) |
| Net Loss Per Share (Basic & Diluted) | $(0.09) | $(0.19) | $(0.20) |
| Cash and Cash Equivalents (Ending) | $1,910 | $1,910 | $995 |
| Short-term Investments (Ending) | $13,687 | $13,687 | $18,653 |
| Total Current Assets | $16,766 | $16,766 | $21,362 |
| Total Liabilities | $2,071 | $2,071 | $2,703 |
| Net Cash Used in Operating Activities | N/A | $(4,407) | $(3,765) |
Note: All figures are in thousands except per share data. The company holds no long-term debt.
Material Changes vs. Prior Period
Operating Expenses: Total operating expenses decreased by approximately $121,000 for the six months ended April 30, 2025, compared to the same period in 2024. This reduction was driven by:
- R&D Expenses: Decreased by $121,000, primarily due to lower outside R&D costs for the ovarian cancer CAR-T therapeutic ($232,000 decrease) and reduced stock-based compensation ($165,000 decrease). These were partially offset by increased spending on a new vaccine discovery program ($113,000 increase) and breast cancer vaccine development ($107,000 increase).
- G&A Expenses: Decreased by $566,000, largely due to reductions in investor/public relations expenses ($442,000), director stock-based compensation ($182,000), and consulting fees ($62,000).
Interest Income: Decreased by $243,000 for the six-month period, attributed to a lower balance of short-term investments and decreased interest rates.
Liquidity: Total cash, cash equivalents, and short-term investments decreased by approximately $4.3 million to $15.6 million as of April 30, 2025, compared to $19.9 million at the end of fiscal year 2024.
Guidance, Outlook, and Risks
Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments are sufficient to fund operations for at least the next twelve months. The company maintains an "at-the-market" equity offering program with approximately $97 million of common stock available for sale.
Future Developments:
- Anticipates reporting final Phase 1 breast cancer vaccine data in December 2025.
- Plans to initiate a Phase 2 clinical trial for the breast cancer vaccine following FDA consultations and protocol development.
- Continuing dose-escalation in the CAR-T ovarian cancer trial, with the study estimated to complete in two to three years.
Risks and Contingencies:
- Capital Needs: The company has not generated revenue from its core programs and expects to incur losses for the foreseeable future. Future funding may be required via equity or debt financing.
- Clinical Uncertainty: Success depends on positive results from human clinical trials, which may take several years. There is no guarantee that licensing deals with pharmaceutical companies will materialize.
- Investment Risk: The company holds Bitcoin-based exchange-traded funds as part of its short-term investments, subject to market volatility.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $15.6 million cash position against the projected burn rate of ~$4.4 million per six months.
- Clinical Milestones: Monitor the timeline for the Phase 2 breast cancer vaccine initiation and the enrollment progress of the fourth dose cohort in the CAR-T trial.
- Equity Dilution: Track the utilization of the $97 million at-the-market offering program and any potential new equity raises.
- Investment Portfolio: Review the composition of short-term investments, specifically the exposure to Bitcoin assets and U.S. Treasury bills, and their impact on interest income.
- Noncontrolling Interest: Note the 4.2% equity stake held by The Wistar Institute in the Certainty Therapeutics subsidiary and its impact on net loss attribution.